About Protagonist Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.protagonist-inc.com/
Frequently Asked Questions
What is the 52-week range for PTGX?
The 52-week high is $160.81 and the 52-week low is $62.24.
What is the P/E ratio for PTGX?
The Price to Earnings (P/E) ratio is 108.57.
What is the dividend yield for PTGX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 12.03%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 29.40%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.88.
Analyst Recommendation Trends
Wall Street analyst consensus for PTGX over the last few months:
Latest PTGX News
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist Therapeutics has a market
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup
PTGX screens strong on growth and setup: 47% EPS growth, no debt, and an 8/10 technical rating with a tight consolidation near resistance.
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup
PTGX clears high-growth momentum and breakout screens, with strong technicals, extreme sales/EPS growth, and a defined setup in clinical-stage biopharma.
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Protagonist Therapeutics, Inc. (PTGX) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 10:40 AM EDTCompany ParticipantsDinesh Patel - CEO,...
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / , Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.
Protagonist Therapeutics Announces $300M Buyback Plan
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the […]
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-10 | PATEL DINESH V PH D | -7,278 | - | - |
| 2026-09-10 | PATEL DINESH V PH D | -7,278 | $144.1 | $1,048,760 |
| 2026-09-10 | PATEL DINESH V PH D | +7,278 | $21.58 | $157,059 |
| 2026-09-09 | PATEL DINESH V PH D | -63,548 | - | - |
| 2026-09-09 | PATEL DINESH V PH D | -63,548 | $146.18 | $9,289,447 |
| 2026-09-09 | PATEL DINESH V PH D | +63,548 | $21.58 | $1,371,366 |
| 2026-09-08 | PATEL DINESH V PH D | -54,174 | - | - |
| 2026-09-08 | PATEL DINESH V PH D | -54,174 | $145.87 | $7,902,361 |
| 2026-09-08 | PATEL DINESH V PH D | +54,174 | $21.58 | $1,169,075 |
| 2026-09-03 | PATEL DINESH V PH D | -510 | - | - |
| 2026-08-11 | PATEL DINESH V PH D | -34,239 | - | - |
| 2026-08-11 | PATEL DINESH V PH D | -34,239 | $148.52 | $5,085,176 |
| 2026-08-11 | PATEL DINESH V PH D | +34,239 | $21.58 | $738,878 |
| 2026-08-10 | PATEL DINESH V PH D | -65,761 | - | - |
| 2026-08-10 | PATEL DINESH V PH D | -65,761 | $149.11 | $9,805,623 |
| 2026-08-10 | PATEL DINESH V PH D | +65,761 | $21.58 | $1,419,122 |
| 2026-06-23 | Waddill William D. | -9,000 | - | - |
| 2026-06-23 | Waddill William D. | -9,000 | $117.94 | $1,061,460 |
| 2026-06-23 | Waddill William D. | +9,000 | $16.54 | $148,860 |
| 2026-06-10 | Waddill William D. | -6,000 | - | - |
| 2026-06-10 | Waddill William D. | -3,000 | - | - |
| 2026-06-10 | Waddill William D. | -9,000 | $107.68 | $969,120 |
| 2026-06-10 | Waddill William D. | +6,000 | $16.54 | $99,240 |
| 2026-06-10 | Waddill William D. | +3,000 | $11.8 | $35,400 |
| 2026-05-29 | Waddill William D. | -9,000 | - | - |
| 2026-05-29 | Waddill William D. | -9,000 | $99.64 | $896,760 |
| 2026-05-29 | Waddill William D. | +9,000 | $11.8 | $106,200 |
| 2026-05-12 | PATEL DINESH V PH D | -75,000 | - | - |
| 2026-05-12 | PATEL DINESH V PH D | -75,000 | $100.12 | $7,509,000 |
| 2026-05-12 | PATEL DINESH V PH D | +75,000 | $21.58 | $1,618,500 |
| 2026-05-12 | PATEL DINESH V PH D | -75,000 | - | - |
| 2026-05-12 | PATEL DINESH V PH D | -75,000 | $100.12 | $7,509,000 |
| 2026-05-12 | PATEL DINESH V PH D | +75,000 | $21.58 | $1,618,500 |
| 2026-05-08 | Giraudo Bryan | -5,130 | $100 | $513,000 |
| 2026-05-08 | Giraudo Bryan | -6,000 | $100 | $600,000 |
| 2026-05-07 | Giraudo Bryan | -12,000 | - | - |
| 2026-05-07 | Giraudo Bryan | -24,000 | - | - |
| 2026-05-07 | Giraudo Bryan | -12,000 | $100.07 | $1,200,840 |
| 2026-05-07 | Giraudo Bryan | -36,000 | $100.14 | $3,605,040 |
| 2026-05-07 | Giraudo Bryan | +12,000 | $6.98 | $83,760 |
| 2026-05-07 | Giraudo Bryan | +24,000 | $6.45 | $154,800 |
| 2026-04-23 | PATEL DINESH V PH D | -1,460 | - | - |
| 2026-04-20 | Ali Asif | -1,750 | $105.47 | $184,573 |
| 2026-03-26 | MOLINA ARTURO MD | -15,000 | - | - |
| 2026-03-26 | MOLINA ARTURO MD | -15,000 | $104.79 | $1,571,850 |
| 2026-03-26 | MOLINA ARTURO MD | +15,000 | $8.04 | $120,600 |
| 2026-03-26 | Ali Asif | -5,265 | - | - |
| 2026-03-26 | Ali Asif | -19,500 | - | - |
| 2026-03-26 | Ali Asif | -24,765 | $104.24 | $2,581,504 |
| 2026-03-26 | Ali Asif | +5,265 | $12.17 | $64,075 |
| 2026-03-26 | Ali Asif | +19,500 | $19.19 | $374,205 |
| 2026-03-26 | SELICK HAROLD E | -24,000 | - | - |
| 2026-03-26 | SELICK HAROLD E | -24,000 | $105 | $2,520,000 |
| 2026-03-26 | SELICK HAROLD E | +24,000 | $12.88 | $309,120 |
| 2026-03-25 | PATEL DINESH V PH D | -54,641 | - | - |
| 2026-03-25 | PATEL DINESH V PH D | -54,641 | $101 | $5,518,741 |
| 2026-03-25 | PATEL DINESH V PH D | +54,641 | $8.58 | $468,820 |
| 2026-03-24 | PATEL DINESH V PH D | -59 | - | - |
| 2026-03-24 | PATEL DINESH V PH D | -59 | $101 | $5,959 |
| 2026-03-24 | PATEL DINESH V PH D | +59 | $8.58 | $506 |
| 2026-03-23 | PATEL DINESH V PH D | -50,000 | - | - |
| 2026-02-17 | Williams Lewis T | +18,000 | - | - |
| 2026-02-17 | Williams Lewis T | -18,000 | $82.42 | $1,483,560 |
| 2026-02-17 | Williams Lewis T | +18,000 | $10.84 | $195,120 |
| 2026-02-06 | Waddill William D. | -20,000 | - | - |
| 2026-02-06 | Waddill William D. | -20,000 | $83.68 | $1,673,600 |
| 2026-02-06 | Waddill William D. | +20,000 | $8.31 | $166,200 |
| 2026-01-27 | Ali Asif | -12,000 | - | - |
| 2026-01-27 | Ali Asif | -16,000 | - | - |
| 2026-01-27 | Ali Asif | -18,203 | $83.14 | $1,513,397 |
| 2026-01-27 | Ali Asif | -28,000 | $83.13 | $2,327,640 |
| 2026-01-27 | Ali Asif | +12,000 | $12.17 | $146,040 |
| 2026-01-27 | Ali Asif | +16,000 | $19.19 | $307,040 |
| 2026-01-27 | MOLINA ARTURO MD | -5,000 | - | - |
| 2026-01-27 | MOLINA ARTURO MD | -5,000 | $82 | $410,000 |
| 2026-01-27 | MOLINA ARTURO MD | +5,000 | $8.04 | $40,200 |
| 2026-01-27 | PATEL DINESH V PH D | -4,068 | - | - |
| 2026-01-27 | PATEL DINESH V PH D | -4,068 | $83.19 | $338,417 |
| 2026-01-27 | PATEL DINESH V PH D | +4,068 | $21.58 | $87,787 |
| 2026-01-26 | MOLINA ARTURO MD | -5,000 | - | - |
| 2026-01-26 | MOLINA ARTURO MD | -5,000 | $82.28 | $411,400 |
| 2026-01-26 | MOLINA ARTURO MD | +5,000 | $8.04 | $40,200 |
| 2026-01-26 | PATEL DINESH V PH D | -14,205 | - | - |
| 2026-01-26 | PATEL DINESH V PH D | -10,685 | - | - |
| 2026-01-26 | PATEL DINESH V PH D | -14,205 | $84.05 | $1,193,930 |
| 2026-01-26 | PATEL DINESH V PH D | +14,205 | $21.58 | $306,544 |
| 2026-01-26 | PATEL DINESH V PH D | -10,685 | $84 | $897,540 |
| 2026-01-26 | PATEL DINESH V PH D | +10,685 | $4.21 | $44,984 |
| 2026-01-23 | MOLINA ARTURO MD | -13,151 | $82.42 | $1,083,905 |
| 2026-01-23 | PATEL DINESH V PH D | -19,315 | - | - |
| 2026-01-23 | PATEL DINESH V PH D | -19,315 | $84.59 | $1,633,856 |
| 2026-01-23 | PATEL DINESH V PH D | +19,315 | $4.21 | $81,316 |
| 2026-01-23 | PATEL DINESH V PH D | -6,000 | - | - |
| 2026-01-20 | MOLINA ARTURO MD | -9,514 | $82.48 | $784,715 |
| 2026-01-20 | Ali Asif | -8,588 | $82.48 | $708,338 |
| 2026-01-20 | PATEL DINESH V PH D | -34,438 | $82.48 | $2,840,446 |
| 2026-01-09 | SELICK HAROLD E | -14,299 | - | - |
| 2026-01-09 | SELICK HAROLD E | +14,299 | $4.21 | $60,199 |
| 2026-01-02 | Waddill William D. | +3,762 | - | - |
| 2026-01-02 | Waddill William D. | +2,695 | - | - |
| 2026-01-02 | Giraudo Bryan | +3,762 | - | - |
| 2026-01-02 | Giraudo Bryan | +2,695 | - | - |
| 2026-01-02 | Williams Lewis T | +3,762 | - | - |
| 2026-01-02 | Williams Lewis T | +2,695 | - | - |
| 2026-01-02 | O'Dowd Sarah A | +3,762 | - | - |
| 2026-01-02 | O'Dowd Sarah A | +2,695 | - | - |
| 2026-01-02 | Ali Asif | +32,000 | - | - |
| 2026-01-02 | Ali Asif | +25,600 | - | - |
| 2026-01-02 | MOLINA ARTURO MD | +32,000 | - | - |
| 2026-01-02 | MOLINA ARTURO MD | +25,600 | - | - |
| 2026-01-02 | SELICK HAROLD E | +3,762 | - | - |
| 2026-01-02 | SELICK HAROLD E | +2,695 | - | - |
| 2026-01-02 | PATEL DINESH V PH D | +120,200 | - | - |
| 2026-01-02 | PATEL DINESH V PH D | +95,400 | - | - |
| 2025-11-21 | PATEL DINESH V PH D | -440 | - | - |
| 2025-11-17 | MOLINA ARTURO MD | -2,712 | $84.77 | $229,896 |
| 2025-10-10 | Waddill William D. | -12,000 | - | - |
| 2025-10-10 | Waddill William D. | -8,000 | $87.81 | $702,480 |
| 2025-10-10 | Waddill William D. | -4,000 | $69.25 | $277,000 |
| 2025-10-10 | Waddill William D. | +12,000 | $6.98 | $83,760 |